The following select publications are from the peer-reviewed literature and discuss the scientific data surrounding the use of OXi4503.
OXi4503 (Combretastatin A1-Phosphate/CA1P)
Clinical—Phase 1 Studies:
Bosse RC, Wasserstrom B, Wise E, Meacham A, Cogle CR. Chemosensitizing leukemia by targeting the leukemia microenvironment with vascular disrupting combretastatins [abstract]. Blood. 2014;124(21):2315.
Cummings J, Zweifel M, Smith N, Ross P, Peters J, Rustin G, et al. Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial. Br J Cancer. 2012;106(11):1766-1771.
Patterson DM, Zweifel M, Middleton MR, Price PM, Folkes LK, Stratford MR, et al. Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. Clin Cancer Res. 2012;18(5):1415-1425.
Turner D, Gonzalez A, Pettiford L, Meacham A, Wise E, Bosse RC, et al. A phase I study of the vascular disrupting combretastatin, OXi4503, in patients with relapsed and refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) [abstract]. Blood. 2013;122(21):1463.
Benezra M, Phillips E, Tilki D, Ding BS, Butler J, Dobrenkov K, et al. Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent. Leukemia. 2012;26(8):1771-1778.
Hua J, Sheng Y, Pinney KG, Garner CM, Kane RR, Prezioso JA, et al. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res. 2003;23(2B):1433-1440.